Posted by Michael Wonder on 29 Sep 2020
Germany has not fully realised its biosimilar potential
29 September 2020 - Investigators have concluded that fully realizing the cost-saving potential of biosimilars could “release enormous resources” for other uses in the German health care system.
Their analysis also found that although “Germany takes a leading role in the amount of biosimilar prescriptions” in the European Union, the nation could realise much greater savings in the cost of cancer care by expanding its use of biosimilars.
Germany’s advancements in biosimilar uptake and its drug price management have been held up as potential models for the United States. Germany has achieved relatively greater savings on biologics through pricing restrictions, negotiations with drug manufacturers, and robust biosimilar competition.
